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Abstract
Background: Traumatic brain injury (TBI) is a major cause of death
and disability. Despite increased awareness, reliable biomarkers are
urgently needed to aid in all forms of traumatic brain injury diagnosis
and prognosis.
Methods: Here, we aim to assess the diagnostic utility of known and
novel TBI biomarkers in a pilot patient cohort of severe TBI (sTBI)
patients and healthy controls. We analyzed concentrations of S100
calcium binding protein B (S100B), neuron specific enolase (NSE),
human kallikrein 6 (hK6) and prostaglandin D2 synthase (PGDS) using
ELISA immunoassays.
Results: Plasma levels of hK6 and PGDS were significantly lower in
sTBI compared with controls, while S100B and NSE were significantly
higher. Furthermore, we show that ratios of NSE and S100B with hK6
and PGDS may be able to determine the presence of sTBI better than
single markers alone.
Conclusions: The findings presented here represent a starting point
for future validation, where biomarker ratios can be tested in
independent TBI cohorts.
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Abbreviations
TBI: Traumatic brain injury, mTBI: mild traumatic brain
injury, sTBI: severe traumatic brain injury, S100B: S100 calcium binding protein B, NSE: neuron specific enolase, hK6:
human kallikrein 6, PGDS: prostaglandin D2 synthase, GCS:
Glasgow Coma Scale, CT: computed tomography, UCH-L1:
ubiquitin C-terminal hydrolase-L1, GFAP: glial fibrillary acidic
protein, PPV: positive predictive value, ROC: receiver operating characteristic, AUC: area under the curve, CI: confidence
interval, LOS: length of stay

Introduction
Traumatic brain injury (TBI) is a significant cause of morbidity,
with an annual incidence of over 65 million cases worldwide1.
TBI is caused by trauma to the head or body that causes neurologic damage and dysfunction. It occurs most often due
to falls, but is also a common occurrence in motor vehicle
collisions, sports and assaults2. These mechanical injuries can
vary in both the severity and the form of injury to the brain3,4.
Generally, presenting TBI may be classified as mild, moderate, or severe. Patients are primarily stratified using the
Glasgow Coma Scale (GCS), a scoring system that evaluates
verbal performance, motor function and eye function. A lower
GCS score indicates a more severe diagnosis and may therefore
indicate the need for further investigations and possibly medical
and/or surgical interventions.
Given the significant burden of disease, reliable diagnostic and
prognostic approaches are urgently needed to guide care. One
promising solution is the quantification of blood biomarkers
capable of delineating the severity of trauma and/or prognostic
outcome. These proteins enter the circulation due to disruption
of brain structures such as the blood brain barrier and/or axons,
leading to a neuroinflammatory response5,6. Although various
markers of mTBI have been identified, a validated panel has
yet to be resolved7. For example, S100 calcium-binding protein B (S100B) and neuron-specific enolase (NSE) are two
well-documented biomarkers with good correlations to TBI
outcome. However, their performance may be limited by nonspecific correlations8,9. The Food and Drug Administration recently
approved the first blood biomarker test to guide head imaging after TBI; it measures ubiquitin C-terminal hydrolase-L1
(UCH-L1) and glial fibrillary acidic protein (GFAP)10. Despite
the approval, concerns have been raised regarding the relatively
low positive predictive value (PPV) of the test and its utility as
a marker for TBI diagnosis specifically11. Given this, it is clear
that there is a need for improved diagnostic TBI biomarkers
with validated efficacy in a clinical setting.
Human kallikrein 6 (hK6) is a serine protease with high brain
and spinal cord expression, particularly in oligodendrocytes12,13.
Previous studies have linked hK6 to brain-related disorders
such as spinal cord injury, where it may play a role in myelin repair14,15. Furthermore, work by our group has demonstrated that serum hK6 may have significant clinical utility as a
prognostic marker of non-traumatic subarachnoid hemorrhage16.
Prostaglandin D synthase (PGDS) is a highly expressed enzyme
that represents nearly 3% of the total protein in cerebral spinal
fluid17. The role of PGDS in hypoxic-ischemic brain injury

has been well-characterized18,19. Therefore, we hypothesize
that hK6 and PGDS may be novel biomarkers of TBI and may
have predictive value in its diagnosis.
In this study, we measured plasma concentrations of multiple proteins in sTBI patients compared with healthy controls.
These markers include those well established in literature
(S100B and NSE), as well as those we hypothesize to be detectable in plasma following TBI – hK6 and PGDS. We reason that
the concentration of these proteins will fluctuate following brain injury, causing them to be more or less abundant in
TBI patient plasma compared with controls. Furthermore, we
hypothesized that the combination of these proteins may be
useful biomarkers to delineate the degree of TBI in patient
populations.

Methods
Study population and sample collection
Plasma samples were obtained using strict standard operating procedures from the Translational Research Centre,
London, Ontario, Canada (https://translationalresearchcentre.
com/). Study protocols were approved by The Western University Health Science Research Ethics Board (REB # 16693) and by
The Mount Sinai Hospital Research Ethics Board (REB
#18-0069-E). Informed consent was obtained either from the
patient or a substitute decision maker.
Blood samples were drawn from adults with severe TBI (sTBI;
n=10), as defined by GCS ≤ 8 with abnormal CT findings, within
24 h of hospital admission. Samples from age-/sex-matched
healthy controls (n=10) were also obtained from the Translational Research Centre. Blood was collected into 3%, 0.109 M
sodium citrate tubes, centrifuged for 15 min (1500 x g at 4 °C),
and the plasma was frozen at −70 °C. Detailed collection and
handling protocols have been described previously20,21. Plasma
samples were transferred on dry ice to Mount Sinai Hospital,
Toronto, Ontario, Canada and stored at -80 °C until analysis.

Measurement of S100B and NSE
The concentrations of S100B and NSE were measured using
electrochemoluminometric immunoassay (Cobas e411 Immunoanalyzer; Roche Diagnostics, Penzberg, Germany) according
to the manufacturer’s protocol, with a detection limit of
0.02 ng/mL and 0.19 ng/mL, respectively. All samples were
thawed at room temperature and analyzed in one run.
Measurement of hK6 and PGDS
For all hK6 measurements, samples were thawed at room temperature, then diluted 10 fold with 6% BSA (Wisent Bioproducts, Quebec, Canada). hK6 was analyzed with an in-house
spectrophotometric ELISA assay with a detection limit of
0.078 ng/mL and dynamic range of 0.078–5 ng/mL22. Briefly,
samples were analyzed in duplicate using an hK6 monoclonal
capture antibody and mouse monoclonal biotinylated detection antibody. White polystyrene 96-well plates were coated
with 400 ng of capture antibody in 100 μl of coating buffer
(50 mmol/L Tris-HCl) and incubated overnight. Plates were
then washed in wash buffer (10 mmol/L Tris-HCl buffer,
150 mmol/L NaCl and 0.5 mL/L Tween 20). 50 μl of diluted
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sample and 50 μl of green assay buffer (60 g/L BSA, 0.1 g/L
goat globulin, 0.02 g/L mouse globulin, 1 g/L bovine globulin,
5 ml/L Tween 20 and 37 g/L KCl) were added to each well
and incubated with shaking for 2 h. Plates were washed,
incubated with 50 ng (100 μl) of detection antibody for 1 h,
washed, and incubated again with 5 ng (100 μl) of alkaline
phosphatase-conjugated streptavidin for 15 min. 100 μl of diflunisal phosphate solution (0.1 M NaOH containing 10 mM
diflunisal phosphate) diluted 1:20 in substrate buffer (0.1 M
Tris, 0.15 M NaCl, 1 mM MgCl2 and 0.05% NaN3) was added
to each well and incubated for 10 min. The reaction was
stopped with 100 µl/well of developing solution (1 M Tris,
0.15 M NaOH, 2 mM TbCl3 and 3 mM EDTA). Excitation at 340 nm and emission at 615 nm was measured with a
time-resolved fluorometer (EnVision, Perkin-Elmer). Samples
were diluted 200 fold in 6% BSA for PGDS analysis
via similar in-house ELISA, with a detection limit of
0.2 ng/mL and dynamic range of 0.2–50 ng/mL, as described
in detail elsewhere23.

Data analysis
Ratios of NSE/hK6, S100B/hK6, NSE/PGDS, S100B/PGDS
were calculated for data analysis. Statistical analyses were
conducted using GraphPad Prism version 6.0e. For receiver
operating characteristic (ROC) analysis, the area under the
curve (AUC) estimates with 95% confidence intervals (CIs) were

calculated using DeLong’s method24. CIs were calculated using
2000 bootstrap replicates each. P-values were calculated using
Wilcoxon signed-rank tests. Spearman correlations were
conducted between biomarker value and lowest-documented GCS
score (within 24 h of hospital admission), as well as hospital
length of stay (LOS). Mann-Whitney U test was used to compare biomarker distribution in patients vs. controls. Two-tailed
student’s t-test was used to compare biomarker concentrations
between patient and control groups. One sTBI subject with
extreme high values for all assays was omitted from data
analysis due to potential sample contamination or processing
error.

Results
Clinical characteristics of recruited patients
Demographics and pathological characteristics of recruited
patients are summarized in Table 1. All raw clinical and biomarker
data are available as Underlying data25.

Use of single biomarkers and ratios to predict sTBI
We used in-house ELISAs and electrochemoluminometric
assays to measure biomarker concentrations in the plasma of
adult sTBI patients and matched healthy controls. Plasma levels of hK6 and PGDS were significantly lower (p = 0.0076 and
p = 0.0172, respectively) in sTBI compared with controls,
while S100B and NSE were significantly higher (p = 0.0002

Table 1. Demographic and clinical information of study participants.
Variable
sTBI (n=10) Healthy controls (n=10)
Age, years*
35.1 (14.4)
35.5 (14.3)
Sex, male/female
7/3
7/3
Lowest documented GCS*†
5.1 (1.45)
Outcome, dead/alive
4/6
ICU LOS, days*
9.1 (6.7)
Hospital LOS, days*
15.4 (18.0)
Etiology, n (%)
Motor vehicle collision
6 (60)
Falls
3 (30)
Abuse/assaults (non accidental)
1 (10)
Admission CT abnormalities, n (%)
Subarachnoid hemorrhage
5 (50)
Subdural hemorrhage
4 (40)
Epidural hemorrhage
2 (20)
Intraventricular hemorrhage
3 (30)
Intraparenchymal hemorrhage
5 (50)
Diffuse axonal injury
6 (60)
Midline shift
2 (20)
Tonsillar herniation
1 (10)
Cerebral contusion
8 (80)
Cerebral edema
2 (20)
Basal skull fractures
6 (60)
Hydrocephalus
1 (10)
Pneumocephalus
2 (20)
GCS, Glasgow Coma Score; ICU, intensive care unit; LOS, length of stay.
*Median (SD).
†

Within 24 h of hospital admission.
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and p = 0.0002, respectively) (Figure 1). All analyzed biomarker ratios (NSE/hK6, S100B/hK6, NSE/PGDS, S100B/PGDS)
showed significant differences in sTBI vs control (p < 0.0001, for
all; Figure 2).
Individual biomarkers and calculated ratios were evaluated to determine their ability to discriminate between sTBI
and control groups. AUC estimates and CIs are presented in
Table 2. Plasma concentrations of NSE, S100B, hK6, PGDS
and all ratios had significant predictive ability to discriminate sTBI from healthy controls (Figure 3, Table 2). Biomarker
ratios showed the highest AUC values (AUC = 1.0, for all),
while NSE and S100B (AUC = 0.967 for both) performed better
than hK6 (AUC = 0.856) and PGDS (AUC = 0.822).

GCS and mortality
There were no significant correlations between any individual biomarker values and lowest-documented GCS score
(Extended data: Supplemental Figures S1, Table S126).
However, ratios of S100B/hK6 (rs = 0.7353, p = 0.0292) and
S100B/PGDS (rs = 0.7899, p = 0.0151) were significantly
associated with GCS score (Figure 4). Finally, we did not
observe any significant differences in biomarker or ratio levels
between sTBI survivors and non-survivors (Extended data:
Supplemental Figures S2 and S326).
Hospital LOS
Plasma concentrations of biomarkers and ratios were compared
to hospital length of stay (LOS) of surviving sTBI patients. LOS

Figure 1. Individual biomarker distribution in the plasma of sTBI patients (n=9) and healthy controls (n=10). Dotted lines represent
group median, bars show interquartile range. Mann Whitney U test; *p < 0.05, **p < 0.01, ***p < 0.001, ns not significant.
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Figure 2. Plasma biomarker ratios in sTBI patients (n=9) and healthy controls (n=10). Dotted lines represent group median, bars show
interquartile range. Mann Whitney U test; ****p < 0.0001.

Table 2. Single biomarker and marker ratio
area under the curve (AUC) values for sTBI
diagnosis.
Biomarker

AUC

95% CI

P value

S100B/hK6

1.0000000 (1, 1)

0.0000217

NSE/hK6

1.0000000 (1, 1)

0.0000217

S100B/PGDS 1.0000000 (1, 1)

0.0000217

NSE/PGDS

1.0000000 (1, 1)

0.0000217

NSE

0.9666667 (0.89, 1)

0.0001516

S100B

0.9666667 (0.89, 1)

0.0001516

hK6

0.8555556 (0.66, 1)

0.0076209

PGDS

0.8222222 (0.62, 1)

0.0172119

was significantly correlated with hK6 (rs = -0.9276, p < 0.006)
and PGDS (rs = -0.9276, p < 0.006), with lower biomarker levels
corresponding to longer LOS (Figure 5, non-significant data not
shown).

Discussion
In this pilot study, we measured plasma concentrations of multiple proteins in sTBI patients compared with age-/sex-matched
healthy controls. We analyzed concentrations of S100B, NSE,
kallikrein 6 (hK6) and prostaglandin D2 synthase (PGDS). We
show that ratios of NSE and S100B with hK6 and PGDS may
be able to determine the presence of sTBI with 100% accuracy.
Plasma levels of hK6 and PGDS were significantly lower
in sTBI compared with controls, while S100B and NSE
were significantly higher (Figure 1). This is consistent with
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Figure 3. Receiver operating characteristic (ROC) curves for plasma biomarkers and biomarker ratios for sTBI diagnosis.
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Figure 4. Biomarker ratio correlation with lowest documented Glasgow Coma Scale (GCS) score in patients with sTBI (n=9).
Spearman’s correlation: (a) S100B/hK6; rs = 0.7353, p = 0.0292; (b) S100B/PGDS; rs = 0.7899, p = 0.0151; (c) NSE/hK6; ns; (d) NSE/PGDS;
ns.

Figure 5. Correlation between hospital length of stay (LOS) in days and plasma biomarker abundance in surviving sTBI patients
(n=6). Spearman’s correlation: (a) hK6; rs = -0.9276, p < 0.006; (b) PGDS; rs = -0.9276, p < 0.006.
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abundant research demonstrating increased S100B and NSE
post-TBI27–29. PGDS has also been shown to be reduced in the CSF
of pediatric patients with inflicted TBI30. To our knowledge, our
findings linking hK6 with sTBI have not been previously reported.

from these experiments may provide valuable insight into TBI
diagnosis and prognosis.

Interestingly, the ratio of NSE/PGDS was able to segregate
sTBI patients from healthy controls better than any marker
alone. We observed one sTBI patient with NSE and S100B values that fell within the control range, but had a NSE/PGDS
and S100B/hK6 value that was clearly higher than controls
(Figure 1 and Figure 2). This suggests that these ratios may
provide better sensitivity in determining the presence of sTBI.
Furthermore, ROC analysis shows higher discriminatory capability in all ratios analyzed (AUC = 1.00, p = 0.0000217)
in comparison with S100B and NSE alone (AUC = 0.967,
p = 0.00015 for both, Figure 3). Taken together, our data suggest that the use of known TBI biomarkers, in conjunction with
PGDS and hK6, may have significant diagnostic capability.

Harvard Dataverse: Underlying data: Discovery of novel
plasma biomarker ratios to discriminate traumatic brain injury.
https://doi.org/10.7910/DVN/VMR7MS25.

Although we did not identify any significant correlations
between individual biomarker concentrations and lowest documented GCS score (Extended data: Supplemental Figures
S126), we found that ratios of S100B/hK6 and S100B/PGDS
were significantly correlated with TBI severity. We observe
that higher ratio values are associated with lower GCS score
in sTBI patients (Figure 4). Furthermore, plasma concentrations of hK6 and PGDS were significantly and negatively associated with hospital LOS (Figure 5). Further investigations
with a larger sample size are needed to confirm the prognostic
utility of these novel findings.
The data presented here represents a pilot study exploring the
utility of four biomarkers and their ratios in diagnosing sTBI.
Overall, it appears that novel ratios of S100B, NSE, PGDS
and kallikrein 6 may have improved TBI diagnostic capability
over any one of these markers alone and may additionally have
prognostic utility. Given the small sample size, these results
must be validated in a larger cohort of TBI patients. Results

Data availability
Underlying data

This project contains the following underlying data:
- biomarker_data (biomarker data, including plasma
concentrations of protein biomarkers and ratio values).
- c linical_data (clinical data, including demographic information and clinical presentation data for each enrolled
patient).

Extended data
Harvard Dataverse: Extended data: Discovery of novel plasma
biomarker ratios to discriminate traumatic brain injury. https://doi.
org/10.7910/DVN/UOOSXE26.
This project contains the following extended data:
- Supplemental Figure S1. Individual biomarker correlation with lowest documented Glasgow Coma Scale
(GCS) score in patients with sTBI (n=9).
- S
 upplemental Figure S2. Differences in individual biomarker concentrations between sTBI patient outcomes (n=9).
-

Supplemental Figure S3. Differences in plasma biomarker
ratios between sTBI patient outcomes (n=9).

- S
 upplemental Table S1. Spearman’s correlation values between biomarkers and lowest documented GCS
score in sTBI patients (n=9).
Data are available under the terms of the Creative Commons
Zero "No rights reserved" data waiver (CC0 1.0 Public domain
dedication).

References
1.

Dewan MC, Rattani A, Gupta S, et al.: Estimating the global incidence of
traumatic brain injury. J Neurosurg. 2018; 1–18.
PubMed Abstract | Publisher Full Text

7.

Jones A, Jarvis P: Review of the potential use of blood neuro-biomarkers in the
diagnosis of mild traumatic brain injury. Clin Exp Emerg Med. 2017; 4(3): 121–7.
PubMed Abstract | Publisher Full Text | Free Full Text

2.

Hutchison MG, Lawrence DW, Cusimano MD, et al.: Head Trauma in Mixed Martial
Arts. Am J Sports Med. 2014; 42(6): 1352–8.
PubMed Abstract | Publisher Full Text

8.

3.

Mckee AC, Daneshvar DH: The neuropathology of traumatic brain injury. Handb
Clin Neurol. 2015; 127: 45–66.
PubMed Abstract | Publisher Full Text | Free Full Text

Pelinka LE, Hertz H, Mauritz W, et al.: Nonspecific increase of systemic neuronspecific enolase after trauma: clinical and experimental findings. Shock. 2005;
24(2): 119–23.
PubMed Abstract | Publisher Full Text

9.

Anderson RE, Hansson LO, Nilsson O, et al.: High serum S100B levels for trauma
patients without head injuries. Neurosurgery. 2001; 48(6): 1255–1258; discussion
1258–60.
PubMed Abstract | Publisher Full Text

10.

Bazarian JJ, Biberthaler P, Welch RD, et al.: Serum GFAP and UCH-L1 for
prediction of absence of intracranial injuries on head CT (ALERT-TBI): a
multicentre observational study. Lancet Neurol. 2018; 17(9): 782–9.
PubMed Abstract | Publisher Full Text

11.

Lindberg DM: Finally, actual data for the FDA-approved biomarkers of traumatic
brain injury. NEJM J Watch. 2018; [cited 2019 Jun 20].
Reference Source

4.

Signoretti S, Lazzarino G, Tavazzi B, et al.: The pathophysiology of concussion.
PM R. 2011; 3(10 Suppl 2): S359–68.
PubMed Abstract | Publisher Full Text

5.

Shlosberg D, Benifla M, Kaufer D, et al.: Blood-brain barrier breakdown as a
therapeutic target in traumatic brain injury. Nat Rev Neurol. 2010; 6(7): 393–403.
PubMed Abstract | Publisher Full Text | Free Full Text

6.

Loane DJ, Byrnes KR: Role of microglia in neurotrauma. Neurotherapeutics.
2010; 7(4): 366–77.
PubMed Abstract | Publisher Full Text | Free Full Text

Page 9 of 15

F1000Research 2019, 8:1695 Last updated: 31 MAR 2022

12.

Shaw JL, Diamandis EP: Distribution of 15 human kallikreins in tissues and
biological fluids. Clin Chem. 2007; 53(8): 1423–32.
PubMed Abstract | Publisher Full Text

13.

Terayama R, Bando Y, Takahashi T, et al.: Differential expression of neuropsin
and protease M/neurosin in oligodendrocytes after injury to the spinal cord.
Glia. 2004; 48(2): 91–101.
PubMed Abstract | Publisher Full Text

14.

15.

16.

Scarisbrick IA, Sabharwal P, Cruz H, et al.: Dynamic role of kallikrein 6 in
traumatic spinal cord injury. Eur J Neurosci. 2006; 24(5): 1457–69.
PubMed Abstract | Publisher Full Text
Bando Y, Ito S, Nagai Y, et al.: Implications of protease M/neurosin in
myelination during experimental demyelination and remyelination. Neurosci
Lett. 2006; 405(3): 175–80.
PubMed Abstract | Publisher Full Text
Martínez-Morillo E, Diamandis A, Romaschin AD, et al.: Kallikrein 6 as a serum
prognostic marker in patients with aneurysmal subarachnoid hemorrhage.
PLoS One. 2012; 7(9): e45676.
PubMed Abstract | Publisher Full Text | Free Full Text

22.

Diamandis EP, Yousef GM, Soosaipillai AR, et al.: Immunofluorometric assay
of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical
applications. Clin Biochem. 2000; 33(5): 369–75.
PubMed Abstract | Publisher Full Text

23.

Melegos DN, Diamandis EP, Oda H, et al.: Immunofluorometric assay of
prostaglandin D synthase in human tissue extracts and fluids. Clin Chem.
1996; 42(12): 1984–91.
PubMed Abstract

24.

DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two
or more correlated receiver operating characteristic curves: a nonparametric
approach. Biometrics. 1988; 44(3): 837–45.
PubMed Abstract | Publisher Full Text

25.

Chen M, Soosaipillai A, Fraser DD, et al.: Underlying data: Discovery of novel
plasma biomarker ratios to discriminate traumatic brain injury. Harvard
Dataverse, V2, 2019.
http://www.doi.org/10.7910/DVN/VMR7MS

26.

Chen M, Soosaipillai A, Fraser DD, et al.: “Extended data: Discovery of novel
plasma biomarker ratios to discriminate traumatic brain injury”. Harvard
Dataverse, V1, 2019.
http://www.doi.org/10.7910/DVN/UOOSXE

17.

Clausen J: Proteins in normal cerebrospinal fluid not found in serum. Proc Soc
Exp Biol Med. 1961; 107: 170–2.
PubMed Abstract | Publisher Full Text

27.

18.

Gonzalez-Rodriguez PJ, Li Y, Martinez F, et al.: Dexamethasone protects
neonatal hypoxic-ischemic brain injury via L-PGDS-dependent PGD2-DP1pERK signaling pathway. PLoS One. 2014; 9(12): e114470.
PubMed Abstract | Publisher Full Text | Free Full Text

Rodríguez-Rodríguez A, Egea-Guerrero JJ, Gordillo-Escobar E, et al.: S100B
and Neuron-Specific Enolase as mortality predictors in patients with severe
traumatic brain injury. Neurol Res. 2016; 38(2): 130–7.
PubMed Abstract | Publisher Full Text

28.

19.

Taniguchi H, Mohri I, Okabe-Arahori H, et al.: Early induction of neuronal
lipocalin-type prostaglandin D synthase after hypoxic-ischemic injury in
developing brains. Neurosci Lett. 2007; 420(1): 39–44.
PubMed Abstract | Publisher Full Text

Berger RP, Pierce MC, Wisniewski SR, et al.: Neuron-specific enolase and
S100B in cerebrospinal fluid after severe traumatic brain injury in infants and
children. Pediatrics. 2002; 109(2): E31.
PubMed Abstract | Publisher Full Text

29.

20.

Gillio-Meina C, Cepinskas G, Cecchini EL, et al.: Translational research in
pediatrics II: blood collection, processing, shipping, and storage. Pediatrics.
2013; 131(4): 754–66.
PubMed Abstract | Publisher Full Text

Böhmer AE, Oses JP, Schmidt AP, et al.: Neuron-specific enolase, S100B, and
glial fibrillary acidic protein levels as outcome predictors in patients with
severe traumatic brain injury. Neurosurgery. 2011; 68(6): 1624–1630; discussion
1630–1.
PubMed Abstract | Publisher Full Text

21.

Daley M, Dekaban G, Bartha R, et al.: Metabolomics profiling of concussion in
adolescent male hockey players: a novel diagnostic method. Metabolomics.
2016; 12(12): 185.
Publisher Full Text

30.

Gao WM, Chadha MS, Berger RP, et al.: A gel-based proteomic comparison
of human cerebrospinal fluid between inflicted and non-inflicted pediatric
traumatic brain injury. J Neurotrauma. 2007; 24(1): 43–53.
PubMed Abstract | Publisher Full Text | Free Full Text

Page 10 of 15

F1000Research 2019, 8:1695 Last updated: 31 MAR 2022

Open Peer Review
Current Peer Review Status:
Version 1
Reviewer Report 23 January 2020

https://doi.org/10.5256/f1000research.22476.r58587
© 2020 Stefani M. This is an open access peer review report distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.

Marco Antonio Stefani
Department of Neurosurgery, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil
This is an interesting study carried out by Chen et al., focusing on human serum biomarkers values
to improve the diagnosis and predict prognosis of severe traumatic brain injury (sTBI). They have
described human kallikrein 6 (hK6) and prostaglandin D2 synthase (PGDS) as potential new
markers of injury, coupled with NSE and S100B.
The methods are clear and the results are very well described. A larger sample is necessary to
confirm the proposed ratios, as pointed out by the authors, so multiple variables can be
combined, increasing the statistic power. In consequence, the conclusions are still limited, but
these findings are promising and worthy of future research.
The pathological/biochemical mechanism to explain the increase of S100B and NSE in sTBI has
been described and makes perfect sense. The protein S100B is produced and released primarily by
astrocytes in the central nervous system and is a peripheral biochemical marker of neural injury,
including reactive gliosis, astrocytic death, and/or blood-brain barrier dysfunction. Neuron-specific
enolase (NSE) is a glycolytic pathway enzyme, predominantly neuronal, so increased
CSF/serum levels of NSE and GFAP indicate neuronal and astrocyte damage.
We are still puzzled by the role of hK6 and PGDS and further research should focus also on
describing the underlying cellular mechanisms related to the presented findings.
It is also noticeable that S100B and NSE proteins are also expressed in other non-neural cell types
under physiological and pathological conditions, so future studies should control for that,
especially in trauma.
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Is the study design appropriate and is the work technically sound?
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Yes
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Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Neurosurgery, clinical and translational research.
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
Reviewer Report 12 November 2019

https://doi.org/10.5256/f1000research.22476.r56390
© 2019 Kobeissy F. This is an open access peer review report distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.

Firas H. Kobeissy
Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of
Beirut, Beirut, Lebanon
We read with interest the study by Chen et al., where the authors have assessed (hK6) and (PGDS)
as new markers of injury indicators coupled with NSE and S100B.
These two proteins [(hK6) and (PGDS)] are of high interest and worth looking at; however, this
study lacks enough power (n=10 exp vs 10 control) which is not enough to draw any kind of
discriminatory level.
N of patients should be increased and other demographic data should be included as well. The TBI
patients assessed are in the severe level and as the authors have mentioned that both UCH-L1 and
GFAP have been considered the gold standard by the FDA specifically for severe TBI which is the
case in this study.
This is in contrast to the S100B and NSE which have been criticized for their non-specificity (muscle
and red blood cells derived!). Thus, I think these data should be contrasted to UCH-L1 and GFAP
with higher N.
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It is of interest as to why the CT scan was not included in the comparison.
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Reviewer Expertise: Brain injury and biomarkers of TBI.
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Time for blood sampling after the brain injury is critical, especially for S100B. Biomarker S100B is
increased within minutes after blood-brain-barrier (BBB) disruption. The passage to the systemic
circulation is critical, especially the fact that only the BBB is damaged and not the brain. Another
point is that most of these markers are expressed to varying degrees outside the central nervous
system.
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If possible a more precise time between injury and sampling would be an additional help in the
interpretation. In the next study, send a sample within the specified time to calculate the
difference in S100B concentrations.
In severe traumatic brain injury, we have cerebrospinal fluid (CSF) as well and it would be helpful
to determine albumin (in CSF and plasma) to see if there is a brain or vessel damage.
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